Delayed Nasdaq Stockholm 07:13:27 2024-04-29 am EDT 5-day change 1st Jan Change
9.81 SEK +6.17% Intraday chart for OssDsign AB +5.03% +22.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain Shares of OssDsign AB are subject to a Lock-Up Agreement Ending on 15-APR-2024. CI
OssDsign Signs Three-year Supply Contract with Premier for Bone, Bone Substitute Products MT
OssDsign AB Wins Long-Term Agreement with Premier, Inc CI
Sweden's OssDsign Names Chief Technical Officer MT
OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer CI
Transcript : OssDsign AB, Q4 2023 Earnings Call, Feb 06, 2024
OssDsign AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
OssDsign AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion CI
OssDsign AB Reports Exceptional Data from the Clinical Study TOP FUSION CI
Ossdsign AB Reports Revenues for the Period October - November 2023 CI
Ossdsign AB Provides Revenue Guidance for the Fourth Quarter of 2023 CI
SEB Venture Capital Sells Full Stake in OssDsign MT
An Unknown buyer acquired 7.6% stake in OssDsign AB (OM:OSSD). CI
Transcript : OssDsign AB, Q3 2023 Earnings Call, Nov 21, 2023
OssDsign AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : OssDsign AB - Special Call
OssDsign to Switch Focus to Orthobiologics Business in US MT
OssDsign Raises SEK150 Million via Share Issue; Stock Rises MT
OssDsign AB Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023 CI
OssDsign Receives FDA Clearance for A New Major Indication CI
OssDsign Wins US FDA Nod for Expanded Use of Nanosynthetic Bone Graft in Interbody Cages MT
Transcript : OssDsign AB, Q2 2023 Earnings Call, Aug 22, 2023
OssDsign AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Certain Shares of OssDsign AB are subject to a Lock-Up Agreement Ending on 29-MAY-2023. CI
Chart OssDsign AB
More charts
OssDsign AB, formerly known as Oss-Q AB is a Sweden-based orthopedic medical device company. It aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The Company uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The Company's customers include neurosurgeons, craniofacial and maxillofacial surgeons.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
  1. Stock Market
  2. Equities
  3. OSSD Stock
  4. News OssDsign AB
  5. Sweden's OssDsign Names Chief Technical Officer